Objective. To evaluate the effect of dual use of VA/Medicare Part D drug benefits on antihypertensive medication supply in older Veterans with dementia. Data Sources/Study Setting. National, linked 2007National, linked -2010 Veterans Affairs (VA) and Medicare utilization and prescription records for 50,763 dementia patients with hypertension. Study Design. We used inverse probability of treatment (IPT)-weighted multinomial logistic regression to examine the association of dual prescription use with undersupply and oversupply of antihypertensives. Data Collection/Extraction Methods. Veterans Affairs and Part D prescription records were used to classify patients as VA-only, Part D-only, or dual VA/Part D users of antihypertensives and summarize their antihypertensive medication supply in 2010: (1) appropriate supply of all prescribed antihypertensive classes, (2) undersupply of ≥1 class with no oversupply of another class, (3) oversupply of ≥1 class with no undersupply, or (4) both undersupply and oversupply. Principal Findings. Dual prescription users were more likely than VA-only users to have undersupply only (aOR = 1.28; 95 percent CI = 1.18-1.39), oversupply only (aOR = 2.38; 95 percent CI = 2.15-2.64), and concurrent under-and oversupply (aOR = 2.89; 95 percent CI = 2.53-3.29), versus appropriate supply of all classes. Conclusions. Obtaining antihypertensives through both VA and Part D was associated with increased antihypertensive under-and oversupply. Efforts to understand how best to coordinate dual-system prescription use are critically needed.
utilization (Stroupe et al. 2017 ), use of high-risk medications in the elderly (Thorpe et al. 2017) , and potentially unsafe opioid use (Gellad et al. 2017b (Gellad et al. , 2018 associated with dual use.
Dual-system prescription use may also impede patients' ability to effectively manage and adhere to prescribed regimens. Patients obtaining prescriptions from multiple, disconnected providers may receive conflicting treatment plans and instructions or experience worse communication with providers, which may hinder their ability to consistently take and/or refill medications for chronic conditions (Chen, Tseng, and Cheng 2013; Hong and Kang 2014; Hansen et al. 2015) . Dual VA and non-VA prescription use may also lead patients to receive more medication than is required (i.e., medication oversupply), if prescribers who are unaware of one another issue duplicate prescriptions (Farley et al. 2011) . Receiving oversupplies of medications could result in adverse events if excess medications are actually taken, and wasted health care resources and increased patient and health system costs even if not taken (Stroupe et al. 2004 (Stroupe et al. , 2006 Krigsman et al. 2007) .
Therefore, obtaining medications from both VA and non-VA systems may represent a unique type of care fragmentation for Veterans that undermines extensive efforts VA has taken to enhance care coordination within the VA through their implementation of Patient-Aligned Care Teams (PACT), VA's version of the patient-centered medical home (Nelson et al. 2014; Schectman and Stark 2014; Yano et al. 2014) . The risk of undersupply and/or oversupply due to dual use of VA and Part D drug benefits may be especially high among complex patients with multiple conditions, who have increased needs for medications and specialty care, but reduced functional and cognitive capacity to navigate multiple health care systems.
Our objective was to evaluate the effect of obtaining chronic disease medications through VA and Part D, versus VA-only, on medication undersupply and oversupply in older Veterans with dementia. We focused on Veterans with dementia because of their increased risk for medication underuse El-Saifi et al. 2018 ) and higher potential vulnerability to care fragmentation. We focused on antihypertensive agents because hypertension is the most common chronic condition affecting patients with dementia (Maslow 2004; Schubert et al. 2006) . A secondary objective was to compare antihypertensive medication supplies for Veterans obtaining all antihypertensive agents through Part D, relative to VAonly users.
METHODS
This study was a secondary analysis of 2007-2010 health care utilization and prescription drug-dispensing data from the VA and Centers for Medicare & Medicaid Services (CMS), for a national cohort of Veterans with dementia dually enrolled in VA and Medicare fee-for-service (FFS) benefits. The Institutional Review Boards at the VA Pittsburgh Healthcare System and the Durham VA Medical Center approved this study.
Data Sources 5378
HSR: Health Services Research 53:6, Part II (December 2018) Sample Figure 1 shows the process of sample selection. VA and CMS data files were obtained for all Veterans aged ≥68 years or older as of January 1, 2010, who had at least one dementia ICD-9 diagnosis code in Medical SAS files or Medicare claims in any of the prior three years (2007) (2008) (2009) . We used the CMS algorithm for Alzheimer's disease or a related disorder to identify diagnosis codes for dementia (Buccaneer Computer Systems & Service, Inc. 2013) , in order to have good sensitivity and specificity compared to a gold-standard clinical dementia assessment (Taylor et al. 2009) (Table S1 ). 
VA-Part D Dual Use and Medication Supply
Antihypertensive classes and specific agents included were defined using the VA NDF (Pharmacy Benefits Management Services 2016); see Table S2 . We searched for all VA and Part D prescription records for fills associated with generic drug names and/or National Drug Codes (NDCs) corresponding to these classes. Fills for combination products were included in calculations for each class in the combination product. (Bryson et al. 2007; Thorpe et al. 2009 Thorpe et al. , 2015 . For patients who entered an inpatient setting or died in 2010, the denominator of the classspecific supply values was decreased to include only days the patient was alive and not in an inpatient setting. Extra days' supply from refills near the end of the year in which days' supply dispensed exceeded number of days left in the year were not included. From these class-specific values, we categorized patients using the following thresholds based on prior research (Stroupe et al. 2000 (Stroupe et al. , 2006 Morris et al. 2006; Krigsman et al. 2007; Yang, Barner, and Worchel 2007; Thorpe et al. 2009 Thorpe et al. , 2015 Hedna et al. 2013; Chen, Blank, and Cheng 2014) : appropriate supply (≥80 percent to <120 percent of days covered) of all classes, undersupply (<80 percent) of at least one antihypertensive class with no oversupply of another class, oversupply (>120 percent) of at least one class with no undersupply of another class, or both undersupply and oversupply of at least one class.
Primary Independent Variable. The primary independent variable was the patient's antihypertensive drug benefit user group, based on where patients filled antihypertensive prescriptions in 2010: 100 percent from VA ("VAonly"); 100 percent from Part D ("Part D-only); or at least one antihypertensive from both VA and Part D ("Dual Use").
Covariates. Past research on dual health care system use (Petersen et al. 2010; Liu et al. 2011 ) and the Andersen Behavioral Model of Health Service Use (Andersen 1995) guided selection of covariates to consider as predictors of antihypertensive user group and potential confounders of the relationship between user group and antihypertensive medication supply. The Andersen model was chosen based on its past use in studies of predictors of medication utilization (Blalock 2011) and supply (Thorpe et al. 2015) . VA encounter records provided data on predisposing factors, including age (68-74, 75-79, 80-84, or ≥85) , sex, and race/ethnicity (white, non-Hispanic; black, non-Hispanic; Hispanic; other). When race/ethnicity was missing in VA data, the Medicare RTI race variable was used (Eicheldinger and Bonito 2008) . The RTI race variable uses the beneficiary's race code in Social Security Administration records together with an algorithm using beneficiary first and last name to identify patients' race and has established validity (Eicheldinger and Bonito 2008) . VA enrollment priority status, an enabling factor, was categorized into four groups associated with generosity of VA health benefits: high disability, , and number of days the patient was alive in 2010. We also counted the total number of unique generic medications (0-5, 6-10, 11-15, ≥15) patients used in 2010. Finally, we included 21 indicators representing the Veteran Integrated Service Network (VISN) of the Veteran's preferred VA facility, as VISN is the main administrative unit in the VHA; each VISN is responsible for service planning and allocation of resources at facilities in their region.
Analytic Approach
Analyses were conducted using Stata v14.2 (StataCorp, College Station, TX, USA). To address missing data for <0.1 percent of patients on three variables (driving distance to VA, census region, and rurality), we used hotdeck imputation, in which missing values are replaced with values from randomly selected sample members with no missing data (Schonlau 2017). We generated descriptive statistics for all covariates and used chi-square and t-tests to test for differences across drug benefit user groups. To test our hypothesis that dual use of VA and Part D prescription benefits to obtain antihypertensives would increase likelihood of medication undersupply and oversupply, we used multinomial logistic regression. We used inverse probability of treatment (IPT) weights to balance the three drug benefit user groups on all covariates. Specifically, we estimated the predicted probability of each "treatment" (VA-only antihypertensive use, Part D-only use, dual use) for each patient, via multinomial logistic regression including all covariates and converted these probabilities into stabilized, inverse probability of treatment weights (Thoemmes and Ong 2015) . These weights were then applied in a weighted multinomial logistic regression model examining the relationship between drug benefit user group and patient-level medication supply categories. We used the "margins" command to calculate the adjusted, average predicted probability of being in each medication supply category for each drug benefit user group. Sensitivity Analyses. We examined robustness of our analyses to two alternative specifications of the medication supply variable: (1) categorizing patient-level summary medication supply using a 110 percent cutoff for defining oversupply (Stroupe et al. 2004; Farley et al. 2011; Chen, Blank, and Cheng 2014) ; and (2) categorizing patient-level summary medication supply using the mean of all class-specific medication supply values for each patient. Also, because descriptive analyses revealed enrollment in Medicaid and/or the Part D lowincome subsidy to be a very strong predictor of dual-system antihypertensive use, we re-estimated unadjusted and IPT-weighted models after stratifying by Medicaid/LIS enrollment. Finally, to examine whether associations between drug benefit user group and medication supply may generalize to other conditions, we conducted a parallel set of analyses on the subsample of Veterans with dementia who had diabetes and were taking oral hypoglycemic agents (OHAs) and otherwise met inclusion/exclusion criteria shown in Figure 1 (except they were required to have diabetes instead of hypertension; n = 13,857). Table 1 shows descriptive characteristics of the sample, overall and by antihypertensive drug benefit user group. The majority was male, White, VA-Part D Dual Use and Medication Supply and aged 80 or older. Only 38 percent had no service-connected disability or low-income status, and a minority was simultaneously enrolled in Medicaid (12 percent) or the LIS (2 percent). A majority of patients used ≥10 unique generic medications in 2010 and most used multiple antihypertensive classes.
RESULTS

Sample Characteristics
Ten percent of patients were dual VA/Part D users of antihypertensives, 70 percent obtained all antihypertensives from VA, and 20 percent obtained all antihypertensives from Part D. Patients differed significantly across drug benefit user groups on all covariates, except for driving distance to nearest VA and presence of lymphoma. The largest magnitudes of differences across user groups were seen for VA priority status, Medicaid/LIS enrollment, health status variables, and medication utilization variables. Dual prescription users (40 percent) and Part D-only users (54 percent) were more likely than VA-only users (34 percent) to not have service-connected disability or low-income status, and were more likely to be enrolled in Medicaid (29 percent and 26 percent vs. 6 percent, respectively). Dual prescription users and Part D-only users had more comorbidities compared to VA-only users, and dual prescription users were more likely than VA-only and Part D-only users to use ≥15 total medications (65 percent vs. 33 percent and 36 percent).
Forty-five percent of Veterans had an appropriate supply of all prescribed antihypertensives; 41 percent had undersupply for ≥1 class (with no oversupply of another class); 10 percent had oversupply for ≥1 class (with no undersupply of another class); and 4 percent simultaneously had oversupply of at least one class and undersupply of another class (Table 2) . Medication supply differed according to drug benefit user group status. Just 32 percent of dual prescription users had an appropriate supply of all prescribed classes, compared to 47 percent of VA-only users and 45 percent of Part D-only users. Dual prescription users were less likely than VA-only users to have undersupply with no oversupply (38 percent vs. 40 percent), but were more likely to have oversupply with no undersupply (19 percent vs. 9 percent), as well as simultaneous oversupply and undersupply (10 percent vs. 4 percent). Part D-only users were more likely to have undersupply with no oversupply (47 percent) but less likely to have oversupply with (3 percent) or without undersupply (5 percent). This pattern remained consistent when using the alternative specifications for the summary medication supply variable.
VA-Part D Dual Use and Medication SupplyIPT-Weighted Regression Models
The application of IPT weights dramatically improved covariate balance across drug benefit user groups (Table S3 ). The only covariates showing statistically significant differences after IPT-weighting included hypothyroidism, psychoses, and total number of unique drugs; however, differences in these characteristics across groups after weighting were very small in magnitude (e.g., after weighting, 36 percent of dual prescription users used ≥15 drugs, compared to 37 percent of VA-only users and 32 percent of Part D-only users). Table 3 shows the results of multinomial regression models for the relationship between antihypertensive drug benefit user group and medication supply. In the IPT-weighted model, dual prescription users (relative to VAonly users) had higher odds of undersupply with no oversupply (OR = 1.28, 95 percent CI = 1.13, 1.44; adjusted predicted probability [APP] 
Sensitivity Analyses
The two alternative IPT-weighted multinomial regression models using a less conservative threshold for defining oversupply and medication supply categories based on mean medication supply values yielded substantively similar results (Tables S4 and S5 ). The pattern of results was also substantively similar in stratified analyses within the Medicaid/LIS-enrollees and nonenrollees (Table S6 ). In analyses for Veterans with dementia and comorbid diabetes (n = 13,857), both unadjusted and IPT-weighted regression models for the relationship between OHA user group status and OHA medication supply categories (Tables S7 and S8 ) yielded similar results compared to hypertension analyses. The only divergent finding was that there was no difference in odds of having simultaneous undersupply and oversupply of OHAs in Part Donly users compared to VA-only users.
DISCUSSION
In a national sample of Veterans with dementia dually enrolled in VA and feefor-service Medicare, we found that Veterans obtaining antihypertensive prescriptions through both VA and Medicare Part D rather than VA alone were less likely to obtain appropriate supplies of antihypertensive medications. Only 32 percent of dual prescription users of antihypertensive agents had an appropriate supply of all prescribed classes in 2010, compared to 47 percent of VA-only users and 45 percent of Part D-only users. In adjusted analyses, dual prescription users were more likely than VA-only users to exhibit undersupply alone, oversupply alone, and simultaneous undersupply and oversupply. Part D-only users were more likely than VA-only users to have undersupply, but less likely to have oversupply. These results were robust to sensitivity analyses using alternative methods to calculate medication supply, stratification by Medicaid/LIS enrollment, and an alternative dependent variable of OHA medication supply instead of antihypertensive supply. We believe this study is the first to examine the effect of dual use of VA and Medicare Part D prescription drug benefits-a potential source of care fragmentation-on patients' under-and overutilization of chronic disease medications. Although only 10 percent of older, Medicare-enrolled Veterans with dementia obtained antihypertensive medications through both sources, our findings suggest that previously documented risks associated with dual use of VA and Part D drug benefits may extend beyond reducing prescribing safety (Thorpe et al. 2017; Gellad et al. 2018) to interfere with patients' ability to maintain appropriate supplies of chronic medications. Our findings are consistent with past studies showing that more outpatient providers (Chen, Tseng, and Cheng 2013; Hong and Kang 2014) and prescribers (Farley et al. 2011; Hansen et al. 2015) are associated with medication undersupply and oversupply. The effect of dual prescription use was present for both undersupply and oversupply, suggesting that dual prescription use may negatively impact patients' appropriate acquisition of medication through multiple mechanisms (e.g., duplicate prescribing, confusing/conflicting instructions, and worse patient-provider communication). The large magnitude of effect of dual versus VA-only prescription use on oversupply suggests that duplicate prescribing within classes may be a particular concern. Future research with family caregivers and health care providers of Veterans with dementia who obtain prescriptions from both VA and Part D, regarding care coordination problems introduced by dual prescription use, may provide insight into which of these potential mechanisms are at play.
VA-Part D Dual Use and Medication Supply
It is notable that 20 percent of dually enrolled Veterans with dementia and hypertension obtained all antihypertensives from non-VA sources through Part D. Among Part D-only users, undersupply was slightly more common than in VA-only users; however, oversupply was less common. These results are consistent with prior studies, in which prevalence of oversupply has been reported to be common among Veterans using the VA (Thorpe et al. 2009 ) but relatively uncommon among non-Veteran Medicare beneficiaries (Thorpe et al. 2015) . The higher rate of undersupply in Part D-only versus VA-Part D Dual Use and Medication SupplyVA-only users may again be explained by greater potential for care fragmentation due to receiving antihypertensive prescriptions from multiple, unconnected non-VA prescribers and/or pharmacies (Marcum et al. 2014) through Part D benefits. On the other hand, duplicate prescriptions from multiple, unconnected non-VA prescribers would likely be identified before they were dispensed when the pharmacy attempts to bill the Part D plan, as most payers employ computerized utilization management systems designed to prevent dispensing of oversupplies (Centers for Medicare & Medicaid Services 2016).
Our results add to growing evidence regarding the importance of improving timely exchange of linked data about VA and non-VA prescriptions across systems of care for both research and clinical care, given nontrivial numbers of Veterans obtaining medications from non-VA sources (Nguyen et al. 2017; Thorpe et al. 2017; Gellad et al. 2018 ) and the consistent association of dual prescription use and worse prescribing outcomes (Thorpe et al. 2017; Gellad et al. 2018 ). VA's partnership with CMS to provide researchers with access to Part D records for Veterans is essential for accurately evaluating prescribing quality in Veterans and supporting research to improve their pharmacotherapy. However, conducting timely research to improve care for Medicare-enrolled Veterans is currently hindered by a two-year lag in availability of Veterans' Part D data for researchers. From a clinical perspective, VA clinicians currently rely almost entirely on patients or their informal caregivers to communicate information about prescriptions from non-VA sources. Early efforts to facilitate health information exchange between VA and non-VA electronic health records (EHRs) for use by clinicians, through the VA Virtual Lifetime Electronic Record (VLER), have shown promise (Byrne et al. 2014 ) and may be a key strategy in reducing care fragmentation and associated prescribing problems. However, further efforts are needed to expand VLER implementation across VA and evaluate its impact on prescribing quality and safety. In addition, pharmacist medication therapy management interventions and nurse case management have both shown promise for improving medication adherence and appropriateness in complex patients (Viswanathan et al. 2012 (Viswanathan et al. , 2015 and should be considered as a strategy to help reduce medication undersupply and oversupply associated with dual prescription use in Veterans with dementia.
Our findings have implications for current efforts to expand Veterans' access to non-VA care through the Veterans Choice Program (VCP) and highlight the need to ensure that VCP use does not undermine VA's efforts to deliver coordinated care. As the VCP allows Veterans to see non-VA providers when they experience VA appointment delays or geographic barriers (Mattocks and Yehia 2017) , it may also lead to Veterans being prescribed medications by non-VA providers to be filled at VA pharmacies. Like non-VA providers seen via Medicare benefits, VCP providers do not have direct, point-of-care access to Veterans' VA EHR to obtain complete information on current prescriptions. As such, they may unknowingly issue duplicate prescriptions or conflicting instructions. Because VCP prescriptions are filled at VA pharmacies and recorded in the EHR, there is an opportunity for VA clinicians to identify and correct prescribing duplications or inefficiencies that does not exist for non-VA prescriptions filled at outside the VA through Part D. However, suboptimal patient-provider communication may also contribute to nonadherence, if prescriptions are issued by new non-VA providers with whom the Veteran does not have an established relationship. Future research should examine the impact of VCP use on medication undersupply and oversupply, as well as pharmacist workload, given preliminary evidence of increased workload for VA pharmacists to resolve prescribing errors and inefficiencies associated with non-VA VCP prescriptions (Gellad et al. 2017a) .
This research has several limitations. First, it is unknown how results generalize to Veterans with other sources of non-VA drug coverage or dual VA-Medicare enrollees without dementia. It is likely that dual prescription use would have a similarly negative impact on medication supply in other older adults with complex medication needs; for example, the vast majority of older adults with multiple chronic conditions. However, these effects may not generalize to younger Veterans with less complex care needs and/or greater functional/cognitive capacity. Research examining the effect of dual VA-Part D prescription use in other Veteran populations is needed, as are studies using linked data for Veterans with other sources of drug coverage.
Second, our measurement of medication supply relies on the assumption that prescriptions filled in the last 120 days of 2009 reflect specific classes of medications patients were instructed to take while outpatients throughout 2010 and does not account for switching from one antihypertensive class to another. When switching between classes occurs, medication supply may be underestimated. However, potential cases of cross-class switching were rare in this sample, occurring in <2 percent of patient-class records. We also have no way of knowing whether oversupplies were actually ingested. Third, although IPT-weighting achieved good balance on covariates, we cannot rule out the possibility that unmeasured confounding factors may bias results. Fourth, due to the lack of prescriber information in the Part D "slim" file, we were unable to examine the role of number of prescribers within a system in addition to dual health system use. And finally, we did not assess for adverse events associated with oversupply or undersupply.
Despite these limitations, this study suggests that utilization of Medicare Part D drug benefits to obtain chronic disease medications may contribute to medication undersupply and oversupply when used simultaneously with VA drug benefits. In addition, patients who solely rely on non-VA prescriptions through Part D rather than VA may also be at greater risk for undersupply. These findings highlight the importance of considering both VA and non-VA prescription drug data when examining the quality of care for Veterans, and suggest that increased efforts by VA and CMS to coordinate prescriptions across systems may be needed to reduce inefficient prescribing and nonadherence associated with dual use of VA-Part D drug benefits. 
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